Slow-injection thymopentin versus placebo in active rheumatoid arthritis
Randomized study in people · 1985
- What was studied
- 41 randomized participants with active rheumatoid arthritis, 21 thymopentin and 20 placebo.
- Main finding
- Between-group clinical findings · At week three, thymopentin performed better than placebo on joint tenderness, swelling, pain on awakening and overall disease activity.
Reported findings and study design
Reported findings
Double-blind comparison of 50 mg IV in divided pushes over 10 minutes, three times weekly for three weeks. The control arm received placebo in the same way. Follow-up continued four weeks after treatment.
Population or model 41 randomized participants with active rheumatoid arthritis, 21 thymopentin and 20 placebo.
Dose, route and schedule
Double-blind comparison of 50 mg IV in divided pushes over 10 minutes, three times weekly for three weeks. The control arm received placebo in the same way. Follow-up continued four weeks after treatment.
Protocol source ↗ · Original indexed abstract and Lancet opening page. The full archive copy requires access.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Between-group clinical findings | At week three, thymopentin performed better than placebo on joint tenderness, swelling, pain on awakening and overall disease activity. | |
| Other measures and follow-up | Left-hand grip did not improve on thymopentin. Placebo improved morning stiffness within the group. Some improvement persisted at four weeks off treatment, with a trend toward relapse. | |
| Laboratory markers and safety | No significant changes in tested laboratory measures. Both arms reported minor side effects. |
Absolute group means and adverse-event counts are unavailable in the accessible pages. The 1984 interim and 1985 supplement reports match the same 21/20 arms, dosing and endpoints. Together the three reports contribute one 41-person cohort.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- Absolute group means and adverse-event counts are unavailable in the accessible pages. The 1984 interim and 1985 supplement reports match the same 21/20 arms, dosing and endpoints. Together the three reports contribute one 41-person cohort.
Related publications may describe some of the same participants or experiments.
Source details
Original indexed abstract and Lancet opening page. The full archive copy requires access.
Sources checked
Added to the library
Citation
M. G. Malaise, C. Hauwaert, P. Franchimont, B. Danneskiold-Samsoe, R. Bach-Andersen, D. Gross, H. Gerber, H. Gerschpacher, H. Stocker, K. Bolla. Slow-injection thymopentin versus placebo in active rheumatoid arthritis The Lancet 1(8433), 832–836
Study source ↗ · DOI 10.1016/S0140-6736(85)92205-6 · Bibliography entry · Link to this summary